343 related articles for article (PubMed ID: 28122742)
1. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
Frismantas V; Dobay MP; Rinaldi A; Tchinda J; Dunn SH; Kunz J; Richter-Pechanska P; Marovca B; Pail O; Jenni S; Diaz-Flores E; Chang BH; Brown TJ; Collins RH; Uhrig S; Balasubramanian GP; Bandapalli OR; Higi S; Eugster S; Voegeli P; Delorenzi M; Cario G; Loh ML; Schrappe M; Stanulla M; Kulozik AE; Muckenthaler MU; Saha V; Irving JA; Meisel R; Radimerski T; Von Stackelberg A; Eckert C; Tyner JW; Horvath P; Bornhauser BC; Bourquin JP
Blood; 2017 Mar; 129(11):e26-e37. PubMed ID: 28122742
[TBL] [Abstract][Full Text] [Related]
2. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.
Fischer U; Forster M; Rinaldi A; Risch T; Sungalee S; Warnatz HJ; Bornhauser B; Gombert M; Kratsch C; Stütz AM; Sultan M; Tchinda J; Worth CL; Amstislavskiy V; Badarinarayan N; Baruchel A; Bartram T; Basso G; Canpolat C; Cario G; Cavé H; Dakaj D; Delorenzi M; Dobay MP; Eckert C; Ellinghaus E; Eugster S; Frismantas V; Ginzel S; Haas OA; Heidenreich O; Hemmrich-Stanisak G; Hezaveh K; Höll JI; Hornhardt S; Husemann P; Kachroo P; Kratz CP; Te Kronnie G; Marovca B; Niggli F; McHardy AC; Moorman AV; Panzer-Grümayer R; Petersen BS; Raeder B; Ralser M; Rosenstiel P; Schäfer D; Schrappe M; Schreiber S; Schütte M; Stade B; Thiele R; von der Weid N; Vora A; Zaliova M; Zhang L; Zichner T; Zimmermann M; Lehrach H; Borkhardt A; Bourquin JP; Franke A; Korbel JO; Stanulla M; Yaspo ML
Nat Genet; 2015 Sep; 47(9):1020-1029. PubMed ID: 26214592
[TBL] [Abstract][Full Text] [Related]
3. Overcoming Microenvironment-Mediated Chemoprotection through Stromal Galectin-3 Inhibition in Acute Lymphoblastic Leukemia.
Tarighat SS; Fei F; Joo EJ; Abdel-Azim H; Yang L; Geng H; Bum-Erdene K; Grice ID; von Itzstein M; Blanchard H; Heisterkamp N
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830047
[TBL] [Abstract][Full Text] [Related]
4. Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.
Nowak D; Liem NL; Mossner M; Klaumünzer M; Papa RA; Nowak V; Jann JC; Akagi T; Kawamata N; Okamoto R; Thoennissen NH; Kato M; Sanada M; Hofmann WK; Ogawa S; Marshall GM; Lock RB; Koeffler HP
Exp Hematol; 2015 Jan; 43(1):32-43.e1-35. PubMed ID: 25450514
[TBL] [Abstract][Full Text] [Related]
5. A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.
Samuels AL; Beesley AH; Yadav BD; Papa RA; Sutton R; Anderson D; Marshall GM; Cole CH; Kees UR; Lock RB
Blood Cancer J; 2014 Aug; 4(8):e232. PubMed ID: 25083816
[TBL] [Abstract][Full Text] [Related]
6. Repurposing anthelmintic agents to eradicate resistant leukemia.
Mezzatesta C; Abduli L; Guinot A; Eckert C; Schewe D; Zaliova M; Vinti L; Marovca B; Tsai YC; Jenni S; Aguade-Gorgorio J; von Stackelberg A; Schrappe M; Locatelli F; Stanulla M; Cario G; Bourquin JP; Bornhauser BC
Blood Cancer J; 2020 Jun; 10(6):72. PubMed ID: 32591499
[TBL] [Abstract][Full Text] [Related]
7. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
Karvonen H; Perttilä R; Niininen W; Hautanen V; Barker H; Murumägi A; Heckman CA; Ungureanu D
Oncogene; 2019 Apr; 38(17):3288-3300. PubMed ID: 30631148
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
Serafin V; Capuzzo G; Milani G; Minuzzo SA; Pinazza M; Bortolozzi R; Bresolin S; Porcù E; Frasson C; Indraccolo S; Basso G; Accordi B
Blood; 2017 Dec; 130(25):2750-2761. PubMed ID: 29101238
[TBL] [Abstract][Full Text] [Related]
9. [Effects of bone marrow stromal cells on the chemotherapeutic sensitivity of acute lymphoblastic leukemia cells].
Wang Y; Han ZX; Zhang JC
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):885-890. PubMed ID: 29262503
[No Abstract] [Full Text] [Related]
10. Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
Brattås MK; Reikvam H; Tvedt THA; Bruserud Ø
Expert Opin Investig Drugs; 2019 May; 28(5):411-420. PubMed ID: 30916583
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells.
Iwasa M; Miura Y; Fujishiro A; Fujii S; Sugino N; Yoshioka S; Yokota A; Hishita T; Hirai H; Andoh A; Ichinohe T; Maekawa T
Int J Hematol; 2017 May; 105(5):587-597. PubMed ID: 28044259
[TBL] [Abstract][Full Text] [Related]
12. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
[TBL] [Abstract][Full Text] [Related]
13. Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia.
Kelvin JM; Chimenti ML; Zhang DY; Williams EK; Moore SG; Humber GM; Baxter TA; Birnbaum LA; Qui M; Zecca H; Thapa A; Jain J; Jui NT; Wang X; Fu H; Du Y; Kemp ML; Lam WA; Graham DK; DeRyckere D; Dreaden EC
J Control Release; 2023 Sep; 361():470-482. PubMed ID: 37543290
[TBL] [Abstract][Full Text] [Related]
14. Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia.
Goto H; Yoshino Y; Ito M; Nagai J; Kumamoto T; Inukai T; Sakurai Y; Miyagawa N; Keino D; Yokosuka T; Iwasaki F; Hamanoue S; Shiomi M; Goto S
Cancer Chemother Pharmacol; 2020 Apr; 85(4):773-783. PubMed ID: 32144432
[TBL] [Abstract][Full Text] [Related]
15. High-throughput screening of human leukemia xenografts to identify dexamethasone sensitizers.
Toscan CE; Failes T; Arndt GM; Lock RB
J Biomol Screen; 2014 Dec; 19(10):1391-401. PubMed ID: 25104793
[TBL] [Abstract][Full Text] [Related]
16. Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.
Eldfors S; Kuusanmäki H; Kontro M; Majumder MM; Parsons A; Edgren H; Pemovska T; Kallioniemi O; Wennerberg K; Gökbuget N; Burmeister T; Porkka K; Heckman CA
Leukemia; 2017 Jan; 31(1):51-57. PubMed ID: 27461063
[TBL] [Abstract][Full Text] [Related]
17. Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing.
Hongo T; Okada S; Inoue N; Yamada S; Yajima S; Watanabe C; Fujii Y; Horikoshi Y
Int J Hematol; 2002 Oct; 76(3):251-9. PubMed ID: 12416736
[TBL] [Abstract][Full Text] [Related]
18. Resistance of t(17;19)-acute lymphoblastic leukemia cell lines to multiagents in induction therapy.
Watanabe A; Inukai T; Kagami K; Abe M; Takagi M; Fukushima T; Fukushima H; Nanmoku T; Terui K; Ito T; Toki T; Ito E; Fujimura J; Goto H; Endo M; Look T; Kamps M; Minegishi M; Takita J; Inaba T; Takahashi H; Ohara A; Harama D; Shinohara T; Somazu S; Oshiro H; Akahane K; Goi K; Sugita K
Cancer Med; 2019 Sep; 8(11):5274-5288. PubMed ID: 31305009
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia.
Yadav BD; Samuels AL; Wells JE; Sutton R; Venn NC; Bendak K; Anderson D; Marshall GM; Cole CH; Beesley AH; Kees UR; Lock RB
Oncotarget; 2016 Sep; 7(37):58728-42. PubMed ID: 27623214
[TBL] [Abstract][Full Text] [Related]
20. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling.
Seyfried F; Demir S; Hörl RL; Stirnweiß FU; Ryan J; Scheffold A; Villalobos-Ortiz M; Boldrin E; Zinngrebe J; Enzenmüller S; Jenni S; Tsai YC; Bornhauser B; Fürstberger A; Kraus JM; Kestler HA; Bourquin JP; Stilgenbauer S; Letai A; Debatin KM; Meyer LH
Cell Death Dis; 2019 Jul; 10(8):571. PubMed ID: 31358732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]